NCT04840641已完成1 期
Flucloxacillin as an Inducer of CYP-enzymes
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Change in Area under curve (AUC) of midazolam
研究概览
简要总结
Worldwide there is an increase in antibiotic resistance which may have potential fatal long-term consequences. This is due to extensive use and sometimes misuse of antibiotics in the treatment of harmless infections.
The aim of this study is to investigate if treatment with flucloxacillin increases drug metabolism in healthy volunteers through induction of cytochrome P450 (CYP) enzymes, CYP1A4, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
The hypothesis is based on an in vitro study showing that flucloxacillin activates a receptor (PXR) responsible for transcription of CYP enzymes.
Trial subjects will ingest flucloxacillin for 31 days and at day 10 and 28 ingest a cocktail of 6 drugs to determine if the CYP enzymes have been induced. Plasma and urine will be drawn over 72 hours to determine the concentration of the 6 drugs and their metabolites.
Change in flucloxacillin concentration will also be measured at day 9 and 27 to establish if flucloxacillin induces its own metabolism.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-55 years
- •The following data have to be in the normal range or only clinical insignificantly different from this: eGFR, ALAT, bilirubin, HbA1c, haemoglobin
- •BMI 18.5 - 29.9 kg m-2
- •Non-smoker (abstained from smoking minimum 2 weeks before the first study day and during the trial)
- •Generally healthy
- •Willing to give informed consent
排除标准
- •Known sensitivity to any of the used drugs or any excipients listed in section 6.1 in the Summary of Product Characteristics (SmPC).
- •Known allergy towards penicillin or cephalosporines
- •Any of the following diseases (current or previous):
- •Heart disease, known family history of prolonged QTc interval, sudden death or conditions that might prolonged QTc-intervals, hypotension, severe disturbance of electrolyte balance e.g. hypokalemia or hypomagnesemia, myasthenia gravis, lung- or respiratory diseases, an anatomically abnormality of the respiratory tract, sleep apnea syndrome
- •Intake of any significant prescription drugs, over-the- counter drugs, herbal drugs or dietary supplements. Contraindicated drugs include: Benzodiazepines, beta blockers, ergot alkaloids, herbal preparations containing St. John's wort, antiarrhythmics, neuroleptics, antidepressive agents, antibiotics, antifungal agents, non-sedating antihistamines, antimalarials, methadone, elbasvir, grazoprevir, nelfinavir cisapride, pimozide, bepridil
- •Alcohol abuse or if the Danish Health Authority recommendation regarding alcohol intake has been exceeded 2 weeks before the first study day (men 14 units alcohol/week, women 7 units alcohol/week)
- •Women who are breastfeeding
- •Positive pregnancy test at inclusion screening or at any of the study days
- •Participation in any other interventional trials
研究组 & 干预措施
Flucloxacillin treatment
Experimental
The investigators measure the concentration of flucloxacillin after 9 and 27 days and the concentration of cocktaildrugs after 10 and 28 days.
干预措施: Flucloxacillin (Drug)
结局指标
主要结局
Change in Area under curve (AUC) of midazolam
时间窗: Baseline and day 28
Change in the activity of the drug metabolizing enzyme CYP3A4
次要结局
- Change in Cmax of the metabolite of caffeine(Day 10 and 28)
- Change in Tmax of caffeine(Day 10 and 28)
- Change in Cmax of caffeine(Day 10 and 28)
- Change in Tmax of the metabolite of caffeine(Day 10 and 28)
- Change in CLr of caffeine(Day 10 and 28)
- Change in CLr of the metabolite of caffeine(Day 10 and 28)
- Change in T1/2 of caffeine(Day 10 and 28)
- Change in T1/2 of the metabolite of caffeine(Day 10 and 28)
- Change in AUC of flucloxacillin(Day 9 and 27)
- Change in AUC of the metabolite of flucloxacillin(Day 9 and 27)
- Change in Cmax of flucloxacillin(Day 9 and 27)
- Change in Cmax of the metabolite of flucloxacillin(Day 9 and 27)
- Change in Tmax of flucloxacillin(Day 9 and 27)
- Change in Tmax of the metabolite of flucloxacillin(Day 9 and 27)
- Change in CLr of flucloxacillin(Day 9 and 27)
- Change in AUC of midazolam(Day 10 and 28)
- Change in AUC of the metabolite of midazolam(Day 10 and 28)
- Change in Peak Plasma concentration (Cmax) of midazolam(Day 10 and 28)
- Change in Cmax of the metabolite of midazolam(Day 10 and 28)
- Change in Time to reach Cmax (Tmax) of midazolam(Day 10 and 28)
- Change in Tmax of the metabolite of midazolam(Day 10 and 28)
- Change in Renal Clearence (CLr) of midazolam(Day 10 and 28)
- Change in CLr of the metabolite of midazolam(Day 10 and 28)
- Change in Elimination half-life (T1/2) of midazolam(Day 10 and 28)
- Change in Cmax of the metabolite of omeprazole(Day 10 and 28)
- Change in Tmax of omeprazole(Day 10 and 28)
- Change in Tmax of the metabolite of omeprazole(Day 10 and 28)
- Change in CLr of omeprazole(Day 10 and 28)
- Change in CLr of the metabolite of omeprazole(Day 10 and 28)
- Change in T1/2 of omeprazole(Day 10 and 28)
- Change in T1/2 of the metabolite of omeprazole(Day 10 and 28)
- Change in AUC of losartan(Day 10 and 28)
- Change in AUC of the metabolite of losartan(Day 10 and 28)
- Change in Cmax of losartan(Day 10 and 28)
- Change in Cmax of the metabolite of losartan(Day 10 and 28)
- Change in Tmax of losartan(Day 10 and 28)
- Change in Tmax of the metabolite of losartan(Day 10 and 28)
- Change in T1/2 of the metabolite of midazolam(Day 10 and 28)
- Change in AUC of metoprolol(Day 10 and 28)
- Change in AUC of the metabolite of metoprolol(Day 10 and 28)
- Change in Cmax of metoprolol(Day 10 and 28)
- Change in Cmax of the metabolite of metoprolol(Day 10 and 28)
- Change in Tmax of metoprolol(Day 10 and 28)
- Change in Tmax of the metabolite of metoprolol(Day 10 and 28)
- Change in CLr of metoprolol(Day 10 and 28)
- Change in CLr of the metabolite of metoprolol(Day 10 and 28)
- Change in T1/2 of metoprolol(Day 10 and 28)
- Change in T1/2 of the metabolite of metoprolol(Day 10 and 28)
- Change in AUC of omeprazole(Day 10 and 28)
- Change in AUC of the metabolite of omeprazole(Day 10 and 28)
- Change in Cmax of omeprazole(Day 10 and 28)
- Change in CLr of losartan(Day 10 and 28)
- Change in CLr of the metabolite of losartan(Day 10 and 28)
- Change in T1/2 of losartan(Day 10 and 28)
- Change in T1/2 of the metabolite of losartan(Day 10 and 28)
- Change in AUC of efavirenz(Day 10 and 28)
- Change in AUC of the metabolite of efavirenz(Day 10 and 28)
- Change in Cmax of efavirenz(Day 10 and 28)
- Change in Cmax of the metabolite of efavirenz(Day 10 and 28)
- Change in Tmax of efavirenz(Day 10 and 28)
- Change in Tmax of the metabolite of efavirenz(Day 10 and 28)
- Change in CLr of efavirenz(Day 10 and 28)
- Change in CLr of the metabolite of efavirenz(Day 10 and 28)
- Change in T1/2 of efavirenz(Day 10 and 28)
- Change in T1/2 of the metabolite of efavirenz(Day 10 and 28)
- Change in AUC of caffeine(Day 10 and 28)
- Change in AUC of the metabolite of caffeine(Day 10 and 28)
- Change in CLr of the metabolite of flucloxacillin(Day 9 and 27)
- Change in T1/2 of flucloxacillin(Day 9 and 27)
- Change in T1/2 of the metabolite of flucloxacillin(Day 9 and 27)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Can flucloxacillin affect other drugs effect?EUCTR2020-004044-28-DKniversity of Southern Denmark14
已完成
不适用
In Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram "-" Pathogens Isolated in RussiaNosocomial InfectionNCT04679610The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)700
已完成
1 期
The Effect of Dicloxacillin on Oral Absorption of DrugsHealthy VolunteersDrug-drug InteractionNCT05073627University of Southern Denmark12
已完成
不适用
Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results StratifiedCystic FibrosisNCT02526004University College Cork223
已完成
不适用
Impact of Cefotaxime and Ceftriaxone on the Emergence and Carrying of Multidrug-Resistant BacteriaInfection, BacterialNCT03903783Fondation Hôpital Saint-Joseph34